串聯臨床、數據與研究
合作洽詢聯絡我們
← 返回研究成果

RESEARCH PUBLICATION / 2024

通信 · Correspondence / Letter

Peficitinib 治療亞洲 RA 患者的第三期隨機試驗

Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study.

The Lancet regional health. Western Pacific

論文與作者

Lancet Reg Health West Pac. 2024;42:100925.

Yue Yang; Jingyang Li; Ju Liu; Lin Liu; Yongfu Wang; Jiankang Hu; Zhijun Li; Jieruo Gu; Xiao Zhang; Zhengyu Xiao; Junjie Zheng; Zhanguo Li; James Cheng-Chung Wei

ABSTRACT · RESEARCH SUMMARY

中文重點摘要

385 名對 methotrexate 反應不足或不耐受的亞洲 RA 患者,隨機接受 peficitinib 100 mg、150 mg 或安慰劑。第 24 週/提早終止時的 ACR20 分別為 56.6%、56.3% 及 24.2%;兩劑量皆優於安慰劑,但較高劑量未見額外優勢。Peficitinib 組帶狀疱疹相關疾病發生率較高,需併同療效評估。

依公開摘要整理研究重點;此段為摘要導讀,非全文翻譯。閱讀原文摘要 ↗